Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec;9(4):421-31.
doi: 10.1007/s11899-014-0234-1.

Stopping higher-risk myelodysplastic syndrome in its tracks

Daniel A Pollyea  1 , Jonathan A Gutman
Affiliations
Review

Stopping higher-risk myelodysplastic syndrome in its tracks

Daniel A Pollyea et al. Curr Hematol Malig Rep. 2014 Dec.

Abstract

Higher-risk myelodysplastic syndromes (MDS) are a collection of diseases associated with poor outcomes from complications related to bone marrow failure and evolution to acute myeloid leukemia. While most patients receive epigenetic therapies, intensive chemotherapy or allogeneic stem cell transplantation, more tolerable and effective treatments are necessary to realize the goal of stopping this disease in its tracks. Recent efforts, building on decades of research exploring the pathogenesis of this disease, have revealed exciting clues that elucidate critical biological features that drive or contribute to MDS, and may serve as targets for selective and well-tolerated future therapies. Here, we review the current diagnostic, prognostic, and therapeutic approaches to higher-risk MDS.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Curr Opin Hematol. 2013 Nov;20(6):494-500 - PubMed
    1. Haematologica. 2010 Feb;95(2):340-2; author reply 343-4 - PubMed
    1. Br J Haematol. 2010 Aug;150(3):293-302 - PubMed
    1. Hematology Am Soc Hematol Educ Program. 2011;2011:550-5 - PubMed
    1. Lancet Oncol. 2009 Mar;10(3):223-32 - PubMed

LinkOut - more resources